Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT02939183 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02939183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02939183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
January 17, 2017
Completion date
October 6, 2022
Enrollment
61 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma